Applied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland.
Methods Mol Biol. 2023;2598:381-390. doi: 10.1007/978-1-0716-2839-3_28.
The use of platelet-rich plasma (PRP) has been supported by encouraging data from in vitro and preclinical in vivo studies, both in terms of safety and efficacy. This led to the wide use of PRP injections in the clinical practice, with promising results especially as a minimally invasive treatment for cartilage degeneration and osteoarthritis (OA). While many controversies remain on the best PRP formulation, the overall available clinical studies support the benefits of PRP, with functional improvement and reduction of pain-related symptoms up to 12 months, especially in young patients and early OA stages.
富血小板血浆（PRP）的使用得到了体外和临床前体内研究数据的支持，无论是在安全性还是有效性方面。这导致 PRP 注射在临床实践中的广泛应用，尤其是作为软骨退变和骨关节炎（OA）的微创治疗方法，取得了良好的效果。虽然对于最佳 PRP 配方仍存在许多争议，但总体上现有的临床研究支持 PRP 的益处，在 12 个月内可改善功能并减轻与疼痛相关的症状，尤其是在年轻患者和 OA 早期阶段。
